

## Catalent completes expansion of clinical supply facility in Shanghai, China

09 December 2022 | News

The Waigaoqiao facility is one of two clinical supply facilities that Catalent operates in Shanghai, the other being in Tangzhen



Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, has completed the expansion of its clinical supply facility in the Waigaoqiao Free Trade Zone (FTZ) in Shanghai, China.

The project has seen the site increase by approximately 30,000 square feet (approximately 2,800 square meters), which has allowed the installation of additional refrigerated (between 2 and 8 degrees Celsius) and deep-frozen (between minus 70 and minus 90 degrees Celsius) storage, and secondary packaging capabilities to be expanded. The completion was marked by two customer events, on Dec. 1 and Dec. 6, where members of Catalent's senior management team showcased the facilities at the site and hosting workshops on clinical supply management and new GMP policies.

"China is the fastest growing clinical trials market in the Asia-Pacific region, and Catalent continues to invest and expand its facilities and services to offer reliable, flexible, and integrated support to customers," said Tracey Clare, General Manager, APAC Operations, Catalent. "These additional capabilities increase the site's ability to support clinical trials for advanced therapeutics, which often require specialized storage and handling capabilities."

The Waigaoqiao facility is one of two clinical supply facilities that Catalent operates in Shanghai, the other being in Tangzhen, outside the FTZ. Together, they provide sponsors with optimized supply solutions for studies being undertaken in China, and through Catalent's extensive network, the Asia-Pacific region and globally. These include clinical supply management, comparator sourcing, FastChain® demand-led supply, primary and secondary packaging, storage, and global distribution, as well as clinical returns and destruction.